I think it does the opposite. I don't believe that would be the case. If we make it longer, they would have more control over the price, and the supply as well. When you give them that possibility of protecting their investment for a longer period of time, that's what becomes a problem in terms of our getting to the point where generic drugs can be developed, or bio-similar drugs can be developed as well.
On April 19th, 2016. See this statement in context.